Literature DB >> 20472890

Differential effects of myopathy-associated caveolin-3 mutants on growth factor signaling.

Eva Brauers1, Agnes Dreier, Andreas Roos, Berthold Wormland, Joachim Weis, Alexander Krüttgen.   

Abstract

Caveolin-3 is an important scaffold protein of cholesterol-rich caveolae. Mutations of caveolin-3 cause hereditary myopathies that comprise remarkably different pathologies. Growth factor signaling plays an important role in muscle physiology; it is influenced by caveolins and cholesterol-rich rafts and might thus be affected by caveolin-3 dysfunction. Prompted by the observation of a marked chronic peripheral neuropathy in a patient suffering from rippling muscle disease due to the R26Q caveolin-3 mutation and because TrkA is expressed by neuronal cells and skeletal muscle fibers, we performed a detailed comparative study on the effect of pathogenic caveolin-3 mutants on the signaling and trafficking of the TrkA nerve growth factor receptor and, for comparison, of the epidermal growth factor receptor. We found that the R26Q mutant slightly and the P28L strongly reduced nerve growth factor signaling in TrkA-transfected cells. Surface biotinylation experiments revealed that the R26Q caveolin-3 mutation markedly reduced the internalization of TrkA, whereas the P28L did not. Moreover, P28L expression led to increased, whereas R26Q expression decreased, epidermal growth factor signaling. Taken together, we found differential effects of the R26Q and P28L caveolin-3 mutants on growth factor signaling. Our findings are of clinical interest because they might help explain the remarkable differences in the degree of muscle lesions caused by caveolin-3 mutations and also the co-occurrence of peripheral neuropathy in the R26Q caveolinopathy case presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472890      PMCID: PMC2893669          DOI: 10.2353/ajpath.2010.090741

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

Review 1.  Purification of caveolae-derived membrane microdomains containing lipid-anchored signaling molecules, such as GPI-anchored proteins, H-Ras, Src-family tyrosine kinases, eNOS, and G-protein alpha-, beta-, and gamma-subunits.

Authors:  M P Lisanti; M Sargiacomo; P E Scherer
Journal:  Methods Mol Biol       Date:  1999

2.  Caveolin interacts with Trk A and p75(NTR) and regulates neurotrophin signaling pathways.

Authors:  T R Bilderback; V R Gazula; M P Lisanti; R T Dobrowsky
Journal:  J Biol Chem       Date:  1999-01-01       Impact factor: 5.157

3.  Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities.

Authors:  J Couet; M Sargiacomo; M P Lisanti
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

4.  Caveolin-3 upregulation activates beta-secretase-mediated cleavage of the amyloid precursor protein in Alzheimer's disease.

Authors:  K Nishiyama; B D Trapp; T Ikezu; R M Ransohoff; T Tomita; T Iwatsubo; I Kanazawa; K K Hsiao; M P Lisanti; T Okamoto
Journal:  J Neurosci       Date:  1999-08-01       Impact factor: 6.167

5.  Caveolin-3 in muscular dystrophy.

Authors:  E M McNally; E de Sá Moreira; D J Duggan; C G Bönnemann; M P Lisanti; H G Lidov; M Vainzof; M R Passos-Bueno; E P Hoffman; M Zatz; L M Kunkel
Journal:  Hum Mol Genet       Date:  1998-05       Impact factor: 6.150

6.  Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues.

Authors:  E Shibayama; H Koizumi
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

7.  TrkA immunoreactivity in reactive astrocytes in human neurodegenerative diseases and colchicine-treated rats.

Authors:  F Aguado; J Ballabriga; E Pozas; I Ferrer
Journal:  Acta Neuropathol       Date:  1998-11       Impact factor: 17.088

8.  Affinity-purification and characterization of caveolins from the brain: differential expression of caveolin-1, -2, and -3 in brain endothelial and astroglial cell types.

Authors:  T Ikezu; H Ueda; B D Trapp; K Nishiyama; J F Sha; D Volonte; F Galbiati; A L Byrd; G Bassell; H Serizawa; W S Lane; M P Lisanti; T Okamoto
Journal:  Brain Res       Date:  1998-09-07       Impact factor: 3.252

9.  M-caveolin, a muscle-specific caveolin-related protein.

Authors:  M Way; R G Parton
Journal:  FEBS Lett       Date:  1996-01-02       Impact factor: 4.124

10.  Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex.

Authors:  F Galbiati; D Volonte; C Minetti; J B Chu; M P Lisanti
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

View more
  6 in total

1.  Tracking Effects of SIL1 Increase: Taking a Closer Look Beyond the Consequences of Elevated Expression Level.

Authors:  Thomas Labisch; Stephan Buchkremer; Vietxuan Phan; Laxmikanth Kollipara; Christian Gatz; Chris Lentz; Kay Nolte; Jörg Vervoorts; José Andrés González Coraspe; Albert Sickmann; Stephanie Carr; René P Zahedi; Joachim Weis; Andreas Roos
Journal:  Mol Neurobiol       Date:  2017-04-11       Impact factor: 5.590

2.  Common membrane trafficking defects of disease-associated dynamin 2 mutations.

Authors:  Ya-Wen Liu; Vasyl Lukiyanchuk; Sandra L Schmid
Journal:  Traffic       Date:  2011-08-05       Impact factor: 6.215

3.  Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances.

Authors:  J T Vollrath; A Sechi; A Dreser; I Katona; D Wiemuth; J Vervoorts; M Dohmen; A Chandrasekar; J Prause; E Brauers; C M Jesse; J Weis; A Goswami
Journal:  Cell Death Dis       Date:  2014-06-12       Impact factor: 8.469

4.  The Caveolin-3 G56S sequence variant of unknown significance: Muscle biopsy findings and functional cell biological analysis.

Authors:  Eva Brauers; Andreas Roos; Laxmikanth Kollipara; René P Zahedi; Alf Beckmann; Nilane Mohanadas; Hartmut Bauer; Martin Häusler; Stéphanie Thoma; Wolfram Kress; Jan Senderek; Joachim Weis
Journal:  Proteomics Clin Appl       Date:  2016-11-14       Impact factor: 3.494

5.  Biochemical and pathological changes result from mutated Caveolin-3 in muscle.

Authors:  José Andrés González Coraspe; Joachim Weis; Mary E Anderson; Ute Münchberg; Kristina Lorenz; Stephan Buchkremer; Stephanie Carr; René Peiman Zahedi; Eva Brauers; Hannah Michels; Yoshihide Sunada; Hanns Lochmüller; Kevin P Campbell; Erik Freier; Denisa Hathazi; Andreas Roos
Journal:  Skelet Muscle       Date:  2018-08-28       Impact factor: 4.912

6.  Dystrophy-associated caveolin-3 mutations reveal that caveolae couple IL6/STAT3 signaling with mechanosensing in human muscle cells.

Authors:  Melissa Dewulf; Darius Vasco Köster; Bidisha Sinha; Christine Viaris de Lesegno; Valérie Chambon; Anne Bigot; Mona Bensalah; Elisa Negroni; Nicolas Tardif; Joanna Podkalicka; Ludger Johannes; Pierre Nassoy; Gillian Butler-Browne; Christophe Lamaze; Cedric M Blouin
Journal:  Nat Commun       Date:  2019-04-29       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.